CCT128930

CCT128930 is a small molecule inhibitor developed as a selective and orally bioavailable inhibitor of Protein kinase B (PKB/Akt). It was designed to target the PKB/Akt pathway with high selectivity and has demonstrated in vivo antitumor activity in preclinical models. The compound is experimental and has not been approved for any indication. Its primary mechanism of action is inhibition of PKB/Akt signaling—a key pathway involved in cell survival and proliferation—making it a potential candidate for cancer therapy[3][6][1].

Other names

1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine4-[ (4-chlorophenyl)methyl ] -1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-methanamine